Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Yamazaki, Daisuke ^a   Ishida, Masaru ^a   Watanabe, Hiroyuki ^a   Nobori, Kiyoshi ^a   Oguma, Yasunori ^a   Terata, Yutaka ^a   Koyama, Takashi ^a   Iino, Kenji ^a   Kosaka, Toshimitsu ^a   Ito, Hiroshi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Secondary prevention; Statin

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVE C REACTIVE PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; EXPLORATORY RESEARCH; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SERUM AMYLOID P-COMPONENT; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873187370     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-9     Document Type: Article

References (46)

1. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Circulation 1990 81 5 1721 1733 10.1161/01.CIR.81.5.1721 2184951 (Pubitemid 20158316)
2. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Ueshima H, Kasagi F, Kodama K, Okamura T, Hayakawa T, Okayama A, Circ J 2006 70 10 1249 1255 10.1253/circj.70.1249 16998254 (Pubitemid 44453215)
3. Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. Teramoto T, Ohashi Y, Nakaya N, Yokoyama S, Mizuno K, Nakamura H, Circ J 2008 72 10 1569 1575 10.1253/circj.CJ-08-0191 18762707
4. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Lancet 2005 366 9493 1267 1278 16214597
5. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, N Engl J Med 2005 352 14 1425 1435 10.1056/NEJMoa050461 15755765 (Pubitemid 40471450)
6. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH, N Engl J Med 1997 336 14 973 979 10.1056/NEJM199704033361401 9077376 (Pubitemid 27152782)
7. C-reactive protein levels and outcomes after statin therapy. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, N Engl J Med 2005 352 1 20 28 10.1056/NEJMoa042378 15635109 (Pubitemid 40075677)
8. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S, Circulation 2001 103 15 1933 1935 10.1161/01.CIR.103.15.1933 11306519 (Pubitemid 32322218)
9. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Albert MA, Danielson E, Rifai N, Ridker PM, JAMA 2001 286 1 64 70 10.1001/jama.286.1.64 11434828 (Pubitemid 32606333)
10. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, N Engl J Med 2001 344 26 1959 1965 10.1056/NEJM200106283442601 11430324 (Pubitemid 32568149)
11. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH, Circulation 2002 106 12 1447 1452 10.1161/01.CIR.0000029743.68247.31 12234946
12. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Circulation 2003 108 13 1560 1566 10.1161/01.CIR.0000091404.09558.AF 12975259 (Pubitemid 37187781)
13. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM, Am J Cardiol 2009 103 3 369 374 10.1016/j.amjcard.2008.09.090 19166691
14. Pleiotropic effects of ezetimibe: do they really exist? Kalogirou M, Tsimihodimos V, Elisaf M, Eur J Pharmacol 2010 633 1-3 62 70 20152830
15. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D, Atherosclerosis 2011 217 Suppl 1 1 44 21722901
16. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL, J Am Coll Cardiol 2008 51 15 1512 1524 10.1016/j.jacc.2008.02.034 18402913 (Pubitemid 351470037)
17. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y, Arterioscler Thromb Vasc Biol 2008 28 7 1385 1391 10.1161/ATVBAHA.107.157164 18403728
18. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Jones P, Kafonek S, Laurora I, Hunninghake D, Am J Cardiol 1998 81 5 582 587 10.1016/S0002-9149(97)00965-X 9514454 (Pubitemid 28182422)
19. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D, Am J Cardiol 2007 99 12 1706 1713 10.1016/j.amjcard.2007.01.062 17560879 (Pubitemid 46874325)
20. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J, Am Heart J 2005 149 3 464 473 10.1016/j.ahj.2004.11.023 15864235 (Pubitemid 40585409)
21. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. Kinlay S, J Am Coll Cardiol 2007 49 20 2003 2009 10.1016/j.jacc.2007.01.083 17512355 (Pubitemid 46734641)
22. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D, Circulation 2005 111 19 2518 2524 10.1161/01.CIR.0000165070.46111.9F 15867169 (Pubitemid 40696141)
23. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Ridker PM, Circulation 2003 107 3 363 369 10.1161/01.CIR.0000053730.47739.3C 12551853 (Pubitemid 36158034)
24. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Saku K, Zhang B, Noda K, Circ J 2011 75 6 1493 1505 10.1253/circj.CJ-10- 1281 21498906
25. Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Pesaro AE, Serrano CV Jr, Fernandes JL, Cavalcanti AB, Campos AH, Martins HS, Maranhao RC, de Lemos JA, Souza HP, Nicolau JC, Int J Cardiol 2012 158 3 400 404 10.1016/j.ijcard.2011.01.062 21334753
26. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A, Int J Cardiol 2001 77 2-3 247 253 11182189 (Pubitemid 32155911)
27. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Ando H, Sugimoto K, Yanagihara H, Tsuruoka S, Saito T, Takamura T, Kaneko S, Fujimura A, Clin Exp Pharmacol Physiol 2008 35 9 1012 1017 10.1111/j.1440-1681.2008.04945.x 18430053
28. Association of statins with inflammatory cytokines: a population-based Colaus study. Lyngdoh T, Vollenweider P, Waeber G, Marques-Vidal P, Atherosclerosis 2011 219 1 253 258 10.1016/j.atherosclerosis.2011.07.117 21855068
29. Identical LDL-cholesterol lowering but non-identical effects on NF-kappaB activity: High dose simvastatin vs combination therapy with ezetimibe. Rudofsky G, Reismann P, Groener JB, Djuric Z, Fleming T, Metzner C, Grafe IA, Bierhaus A, Nawroth PP, Atherosclerosis 2012 223 1 190 196 10.1016/j.atherosclerosis. 2012.04.003 22633472
30. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F, Arterioscler Thromb Vasc Biol 2005 25 6 1231 1236 10.1161/01.ATV.0000163840.63685.0c 15790934 (Pubitemid 40776614)
31. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Voleti B, Agrawal A, Mol Immunol 2006 43 7 891 896 10.1016/j.molimm.2005.06.045 16054696 (Pubitemid 41814407)
32. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Mayer C, Gruber HJ, Landl EM, Pailer S, Scharnagl H, Truschnig-Wilders M, Marz W, Int J Clin Pharmacol Ther 2007 45 6 319 327 17595889 (Pubitemid 46895050)
33. Ezetimibe and vascular inflammation. Ishibashi T, Takeishi Y, Curr Vasc Pharmacol 2011 9 1 99 108 10.2174/157016111793744788 21044014
34. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. Ohbayashi H, Miyazawa C, Miyamoto K, Sagara M, Yamashita T, Onda R, J Atheroscler Thromb 2009 16 4 490 500 10.5551/jat.No613 19729861
35. Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Iwata A, Miura S, Tanaka T, Ike A, Sugihara M, Nishikawa H, Kawamura A, Saku K, Coron Artery Dis 2012 23 5 315 321 10.1097/MCA.0b013e328352ffec 22617341
36. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T, Arterioscler Thromb Vasc Biol 2007 27 1 161 167 10.1161/01.ATV.0000252126.48375.d5 17095712 (Pubitemid 46360394)
37. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. Arimura T, Miura S, Ike A, Sugihara M, Iwata A, Nishikawa H, Kawamura A, Saku K, J Cardiol 2012 60 2 111 118 10.1016/j.jjcc.2012.03.002 22542530
38. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ, Am J Cardiol 2010 105 1 69 76 10.1016/j.amjcard.2009.08.651 20102893
39. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss HP, Rauch U, J Am Coll Cardiol 2007 49 10 1035 1042 10.1016/j.jacc.2006.10.064 17349882 (Pubitemid 46349499)
40. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. Kurobe H, Aihara K, Higashida M, Hirata Y, Nishiya M, Matsuoka Y, Kanbara T, Nakayama T, Kinoshita H, Sugano M, Fujimoto E, Kurobe A, Sugasawa N, Kitaichi T, Akaike M, Sata M, Matsumoto T, Kitagawa T, J Atheroscler Thromb 2011 18 12 1080 1089 10.5551/jat.9548 22027560
41. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, N Engl J Med 2007 357 13 1301 1310 10.1056/NEJMoa064278 17898099 (Pubitemid 47481452)
42. Effects of dalcetrapib in patients with a recent acute coronary syndrome. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, N Engl J Med 2012 367 22 2089 2099 10.1056/NEJMoa1206797 23126252
43. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Grover SA, Kaouache M, Joseph L, Barter P, Davignon J, Arch Intern Med 2009 169 19 1775 1780 10.1001/archinternmed.2009.328 19858435
44. Simvastatin with or without ezetimibe in familial hypercholesterolemia. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, N Engl J Med 2008 358 14 1431 1443 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
45. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, Horibata Y, Hirai T, Sakamoto T, Yoshimura M, Yamashita Y, Ogawa H, J Am Coll Cardiol 2005 46 11 2022 2030 10.1016/j.jacc.2005.04.070 16325036 (Pubitemid 41713586)
46. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M, Circ J 2012 76 1 221 229 10.1253/circj.CJ-11-0887 22094911